
Advertise on podcast: HealthTree Podcast for Multiple Myeloma
Rating
5from
This podcast has
183 episodes
Language
EnglishPublisher
HealthTree Podcast for MMExplicit
No
Date created
2013/08/04
Latest episode
2026/11/03
Average duration
55 min.
Release period
61 days
Description
HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
Unlock HealthTree Podcast for Multiple Myeloma podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Social media
Check HealthTree Podcast for Multiple Myeloma social media presence
Podcast episodes
Check latest episodes from HealthTree Podcast for Multiple Myeloma podcast
Studying Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia Patients
2026/11/03
In this episode of the HealthTree Podcast for Multiple Myeloma, Jenny Ahlstrom talks with Dr. Douglas Sborov of Huntsman Cancer Institute about plasma cell leukemia (PCL), a rare, aggressive disorder diagnosed when 5% or more plasma cells circulate in the blood. PCL often carries high-risk genetics, has been left out of most clinical trials, and even with modern therapy has a median overall survival of about three years.
Dr. Sborov leads QUANTUM, a national trial for newly diagnosed primary PCL. All patients receive Dara-KRd and a transplant, then are randomized to Dara-KRd or the bispecific teclistamab, followed by carfilzomib and lenalidomide maintenance. He encourages PCL patients to join HealthTree so researchers can better understand this disease.
Answering the Transplant Question for Newly Diagnosed Patients - The FASTER Study
2026/10/12
For three decades, a stem cell transplant has been a standard part of care for newly diagnosed myeloma patients who are eligible for one. But with powerful immunotherapies moving earlier into treatment, a question patients ask us constantly is finally being put to the test: is transplant still necessary?
Dr. Timothy Schmidt of the University of Wisconsin joins us to discuss FASTER, a COMMIT consortium trial he co-chairs. After induction therapy, FASTER randomly assigns patients to either a bispecific antibody combination — elranatamab plus daratumumab — or to transplant followed by standard maintenance. MRD testing then guides what happens next. Patients with disease still detectable after a year cross over to the other approach, and patients who reach sustained MRD negativity may be able to stop treatment entirely and simply be watched.
We talk about what transplant really asks of a patient, who might still need one, how bispecific antibodies work, infection risk and how it's managed, and what it means to stop myeloma treatment after years of being told maintenance continues indefinitely.
Inobrodib: A New Oral Myeloma Treatment with Dr. Nisha Joseph
2026/08/28
A new oral myeloma treatment is now in development. It doesn't work like anything else in your treatment history and has activity in patients who've run out of options. Join us as Dr. Nisha Joseph of Emory's Winship Cancer Institute breaks down how Inobrodib works, who it might help, and where it fits in the future of myeloma care.
Myths vs. Facts about Diet in Multiple Myeloma
2026/02/24
Listen to this episode where Dr. Urvi Shah will talk about the myths and facts about food and how our diet impacts our outcomes when it comes to our myeloma journey
The 2026 Multiple Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson Cancer Center
2026/01/23
The year 2026 brings new promise in multiple myeloma with a wide variety of treatment options available for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies, combination approaches and clinical trials to watch as the research continues advancing at a rapid pace in myeloma.
2025 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute
2025/09/02
The world of immunotherapy in multiple myeloma is exploding - with new treatments being FDA-approved and others working their way through the FDA approval process. In this show, Dr. Paul Richardson focuses on the innovation in immunotherapy that we've seen in the first half of 2025. This includes a discussion about CAR T, bispecific and trispecific antibodies, and a deeper dive on a new class of drugs in myeloma called Antibody Drug Conjugates, with a drug called belantamab mafodotin going through the FDA review process, with a hopeful approval in October of this year.
2025 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute
2025/09/02
Multiple myeloma treatment is advancing in promising ways. Learn about mid-year updates in multiple myeloma from the ASCO and EHA conferences and what to expect from the upcoming International Myeloma Society (IMS) meeting with Paul Richardson, MD, Dana Farber Cancer Institute.
Minimal Residual Disease (MRD) Testing with Dr. Rafael Fonseca
2025/04/04
Learn more about Minimal Residual Disease (MRD) testing and how it’s being used today in research and for your myeloma care. Join Rafael Fonseca, MD, Mayo Clinic to learn when MRD testing should be done and how the results should be used in myeloma care
Preventing Myeloma Progression with Diet: The Nutrivention-2 Stu
2025/03/03
Through her extensive (and continuing) research, Dr. Urvi Shah, a multiple myeloma specialist at Memorial Sloan Kettering Cancer Center, is determined to find answers to the often-asked question by patients with precursor myeloma conditions, “What diet is best for me?” l
Can a plant based diet affect your overall health? Can it affect your blood cancer progression or time to relapse? What does the science say about it, and what questions still need to be answered? Join us to discuss these topics and answer these questions and more.
HealthTree is working with Dr. Urvi Shah's team at MSK in "Nutrivention-2", a national, multi-arm, randomized prospective telehealth study for MGUS and smoldering myeloma patients. This study will explore the microbial changes in response to a plant-based diet and supplements in smoldering myeloma patients. You can learn more about it HERE. If you're interested and want more information, please contact our support team - [email protected].
The Future of Bispecific Antibodies with Dr. Philippe Moreau
2025/02/12
Bispecific antibodies are a growing class of treatment in multiple myeloma. Learn from global expert and International Myeloma Society (IMS) President Dr. Philippe Moreau about the advances being made in bispecific antibodies and what clinicians are learning about how and when to best use this therapy. Dr. Moreau will provide a review of approved and in-development bispecific antibodies, side effect management and more. Learn how HealthTree and IMS are partnering on the HealthTree Bispecific Antibody Study to provide more data and patient experiences to help the research community come to faster conclusions about this new, exciting treatment.
A Look into the 2025 Multiple Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson Cancer Center
2025/02/01
Learn about what's here and what's coming in 2025 in multiple myeloma care with myeloma expert Robert Orlowski, MD, PhD
Driving New Discoveries in Myeloma Research with Dr. Brian Van Ness from the University of Minnesota
2024/12/31
New discoveries in multiple myeloma are made possible through a deep understanding of the disease. Many researchers contribute significantly to these breakthroughs by performing essential lab work, often without ever treating patients directly.
In this episode, we’re joined by Dr. Brian Van Ness, a PhD researcher from the University of Minnesota who has dedicated decades to studying the biology and genetics of multiple myeloma. Dr. Van Ness shares how his lab research has laid the foundation for new insights into this complex disease and how his unwavering love for patients has driven his work during his extensive career.
Tune in to learn how cutting-edge research translates into better outcomes for the myeloma community and how researchers like Dr. Van Ness are shaping the future of care.
2024 Mid-Year Myeloma Review with Paul Richardson, MD, Dana Farber Cancer Institute
2024/11/07
Learn about the latest in multiple myeloma advances with Paul Richardson, MD who will cover the recent American Society of Hematology and European Hematology Association meeting findings.
The Latest in Amyloidosis Care and Research with Morie Gertz, MD, Mayo Clinic
2024/07/18
Dr. Morie Gertz joins the HealthTree Podcast for Multiple Myeloma to share the challenges, treatments and futures of AL amyloidosis and invites amyloidosis patients to join this survey about their diagnosis experience.
Creating a Risk Profile to Personalize Myeloma Care with Ola Landgren, MD, PhD, University of Miami
2024/07/15
Dr. Ola Landgren shares a clinical trial about smoldering myeloma. Join the REVIVE trial study for high-risk smoldering myeloma study here.
He also share about his research partnership with HealthTree on a personalized medicine study that creates a computerized model of risk prediction and treatment recommendations for newly diagnosed patients.
This is a study that is open to all myeloma patients regardless of where they are being treated. The only involvement by patients is to sign a consent form and connect their medical records which requires less than 5 minutes of participation.
Podcast reviews
Read HealthTree Podcast for Multiple Myeloma podcast reviews
100West 2024/03/14
Bringing awareness and knowledge on MM
Well structure conversations with top specialists in the field of MM. A must subscription for patients, caregivers and professionals.
77 Vette 2013/08/20
one more step towards a cure for myeloma
This is a great service that you are providing to myeloma patients and care givers. Thank you and keep up the great work on your journey to find a cur...
Podcast sponsorship advertising
Start advertising on HealthTree Podcast for Multiple Myeloma relevant audience podcasts
You may also like to advertise on these Podcasts

4.9328601398
REAL AF with Andy Frisella
Andy Frisella

3.99067574
20/20
ABC News

4.91366715
The Learning Leader Show With Ryan Hawk
Ryan Hawk

4.92110504
the bossbabe podcast
Natalie Ellis

4.3387082001
The Megyn Kelly Show
SiriusXM

4.947999419
The Shawn Ryan Show
Shawn Ryan

4.5185359
Who, When, Wow!
Tinkercast | Wondery

4.6688691128
Armchair Expert with Dax Shepard
Armchair Umbrella

4.9554862201
The MeidasTouch Podcast
MeidasTouch Network

4.639655
Only Murders in the Building Podcast
Straw Hut Media
